Literature DB >> 33279641

The CUL3/neddylation inhibitor MLN4924 reduces ethanol-induced locomotor sensitization and inflammatory pain allodynia in mice.

Zhong Ding1, Gregory T Knipp2, Richard M van Rijn3, Julia A Chester4, Val J Watts5.   

Abstract

Heterologous sensitization of adenylyl cyclase (AC) is defined by an enhanced cAMP response following persistent activation of Gαi/o-coupled receptors. This phenomenon was first observed in cellular models, and later reported in animal models of inflammatory pain or following chronic exposure to drugs of abuse including opioids and cocaine. Recently, we used genome-wide siRNA screening to identify Cullin3 signaling as a mediator of AC sensitization in cellular models. We also showed that pharmacological inhibition of Cullin3 with the neddylation inhibitor, MLN4924, abolished heterologous sensitization of several AC isoforms, including AC1, AC2, AC5, and AC6. Because ACs, especially AC1, have been implicated in alcohol-induced locomotor sensitization and inflammatory pain, we assessed the potential activity of MLN4924 in both murine models. We found that MLN4924 (30 mg/kg, i.p.) accumulated in the brain and reduced both locomotor sensitization induced by repeated alcohol administration and allodynia in an inflammatory pain model. Based on our previous findings that MLN4924 potently blocks AC sensitization in cellular models, we propose that the activity of MLN4924 in both animal models potentially occurs through blocking AC sensitization. Our findings provide the basis for understanding the molecular mechanism and yield a new pathway for drug development for pathological disorders associated with AC sensitization.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenylyl cyclase; Alcohol; Heterologous sensitization; Inflammatory pain; Locomotor sensitization; MLN4924; Neddylation; Substance use disorder

Mesh:

Substances:

Year:  2020        PMID: 33279641      PMCID: PMC7855618          DOI: 10.1016/j.bbr.2020.113051

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  25 in total

Review 1.  Sensitization of adenylate cyclase by Galpha i/o-coupled receptors.

Authors:  Val J Watts; Kim A Neve
Journal:  Pharmacol Ther       Date:  2005-03-02       Impact factor: 12.310

2.  Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.

Authors:  Wei Hua; Chunjie Li; Zixiao Yang; Lihui Li; Yanan Jiang; Guangyang Yu; Wei Zhu; Zhengyan Liu; Shengzhong Duan; Yiwei Chu; Meng Yang; Yanmei Zhang; Ying Mao; Lijun Jia
Journal:  Neuro Oncol       Date:  2015-04-22       Impact factor: 12.300

3.  Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties.

Authors:  Tarsis F Brust; Doungkamol Alongkronrusmee; Monica Soto-Velasquez; Tanya A Baldwin; Zhishi Ye; Mingji Dai; Carmen W Dessauer; Richard M van Rijn; Val J Watts
Journal:  Sci Signal       Date:  2017-02-21       Impact factor: 8.192

4.  Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus.

Authors:  R S Duman; J F Tallman; E J Nestler
Journal:  J Pharmacol Exp Ther       Date:  1988-09       Impact factor: 4.030

Review 5.  Gα(i/o)-coupled receptor-mediated sensitization of adenylyl cyclase: 40 years later.

Authors:  Tarsis F Brust; Jason M Conley; Val J Watts
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

6.  Genetic elimination of behavioral sensitization in mice lacking calmodulin-stimulated adenylyl cyclases.

Authors:  Feng Wei; Chang Shen Qiu; Susan J Kim; Lisa Muglia; James W Maas; Victor V Pineda; Hai Ming Xu; Zhou Feng Chen; Daniel R Storm; Louis J Muglia; Min Zhuo
Journal:  Neuron       Date:  2002-11-14       Impact factor: 17.173

7.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

8.  Inhibition of morphine tolerance and dependence by diazepam and its relation to cyclic AMP levels in discrete rat brain regions and spinal cord.

Authors:  M J Sheu; P Sribanditmongkol; D N Santosa; G A Tejwani
Journal:  Brain Res       Date:  1995-03-27       Impact factor: 3.252

9.  Adenylyl Cyclase 1 Is Required for Ethanol-Induced Locomotor Sensitization and Associated Increases in NMDA Receptor Phosphorylation and Function in the Dorsal Medial Striatum.

Authors:  Kelly E Bosse; Max F Oginsky; Laura L Susick; Sailesh Ramalingam; Carrie R Ferrario; Alana C Conti
Journal:  J Pharmacol Exp Ther       Date:  2017-08-24       Impact factor: 4.030

10.  Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Authors:  A Craig Lockhart; Todd M Bauer; Charu Aggarwal; Carrie B Lee; R Donald Harvey; Roger B Cohen; Farhad Sedarati; Tsz Keung Nip; Hélène Faessel; Ajeeta B Dash; Bruce J Dezube; Douglas V Faller; Afshin Dowlati
Journal:  Invest New Drugs       Date:  2018-05-21       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.